Isomorphic Chief Executive Officer Demis Hassabis said that the lab plans to use the new capital to accelerate its move toward clinical trials. Isomorphic Labs funding reached $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, but the Alphabet-owned AI drug design company disclosed no human trial, no named clinical.